Allyx Therapeutics
February 26, 2024
CNS/Neurological
Allyx Therapeutics was founded in 2019 by a group of seasoned biopharma industry executives, venture capitalists, and scientific experts. The company aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, ALX-001 is a first-in-class oral therapy with a unique mechanism of action at mGluR5 currently in clinical development in Alzheimer’s disease and Parkinson's disease.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}